Plain-English translation of NCT07323056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications——given before surgery to patients with advanced lung cancer that has an EGFR mutation. The goal is to shrink the tumor before surgery so it becomes easier to remove completely. Researchers also want to understand which patients benefit most from this treatment approach.
For people with advanced lung cancer that cannot be operated on immediately, there is a need for effective treatments that can shrink tumors enough to make surgery possible. This medication combination may offer better results than current options and could help more patients become eligible for surgery.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications (likely as infusions and oral tablets) over several weeks before surgery. During this time, you'll have regular clinic visits for blood tests, imaging scans, and monitoring of side effects. Once the medical team determines the tumor has shrunk enough, you'll have surgery to remove it. The trial involves about 36 patients total, and you would be followed to see how well the treatment worked and how safe it was.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China